Undetectable gadolinium brain retention in individuals with an age‐dependent blood‐brain barrier breakdown in the hippocampus and mild cognitive impairment
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Introduction: Blood‐brain barrier (BBB) breakdown is an early independent biomarker of human cognitive dysfunction, as found using gadolinium (Gd) as a contrast agent. Whether Gd accumulates in brains of individuals with an age‐dependent BBB breakdown and/or mild cognitive impairment remains unclear. Methods: We analyzed T1‐weighted magnetic resonance imaging (MRI) scans from 52 older participants with BBB breakdown in the hippocampus 19‐28 months after either cyclic or linear Gd agent. Results: There was no change in T1‐weighted signal intensity between the baseline contrast MRI and unenhanced MRI on re‐examination in any of the studied 10 brain regions with either Gd agent suggesting undetectable Gd brain retention. Discussion: Gd does not accumulate in brains of older individuals with a BBB breakdown in the hippocampus. Thus, Gd agents can be used without risk of brain retention within a ∼2‐year follow‐up to study BBB in the aging human brain in relation to cognition and/or other pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Self-citationBlood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312 · cited 1×
“BBB breakdowns in neurodegenerative disorders with vascular, cognitive, and/or motor dysfunction, such as AD and related dementias, and PD, HD, and others, respectively [34,35], is increasing.”
BackgroundSelf-citationBlood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Self-citationBlood–brain barrier breakdown is an early biomarker of human cognitive dysfunction
Nation, D. A., Sweeney, M. D., Montagne, A., Sagare, A. P., D’Orazio, L. M., Pachicano, M., Sepehrband, F., Nelson, A. R., Buennagel, D. P., Harrington, M. G., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0297-y · Cited by 1,728
Self-citationThe role of brain vasculature in neurodegenerative disorders
Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W., & Zlokovic, B. V. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0234-x · Cited by 998
Self-citationMorris, J. C., Weintraub, S., Chui, H. C., Cummings, J., DeCarli, C., Ferris, S., Foster, N. L., Galasko, D., Graff-Radford, N., Peskind, E. R., et al. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213865.09806.92 · Cited by 950
Self-citationImpact of multiple pathologies on the threshold for clinically overt dementia
Kapasi, A., DeCarli, C., & Schneider, J. A. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1717-7 · Cited by 739 · cited 2×
“, atherosclerosis, arteriolosclerosis, gross infracts, microinfarcts, and/or cerebral amyloid angiopathy) as a major contributor to their cognitive dysfunction, whereas only 7% of individuals develop MCI attributable to only Ab and tau pathology [48].”
BackgroundVascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711 · cited 5×
“AD is increasingly recognized as multifactorial and heterogeneous disorder, and vascular dysfunction is a notable contributor to AD pathophysiology [33].”
BackgroundInfluentialSelf-citationHalliday, M. R., Rege, S. V., Ma, Q., Zhao, Z., Miller, C. A., Winkler, E. A., & Zlokovic, B. V. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.44 · Cited by 649
Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease
van de Haar, H. J., Burgmans, S., Jansen, J. F. A., van Osch, M. J. P., van Buchem, M. A., Muller, M., Hofman, P. A. M., Verhey, F. R. J., & Backes, W. H. (2016) · Radiology · doi:10.1148/radiol.2016152244 · Cited by 601
Microvascular injury and blood–brain barrier leakage in Alzheimer's disease
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V., & Stopa, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.016 · Cited by 487
Striatal Blood–Brain Barrier Permeability in Parkinson'S Disease
Gray, M. T., & Woulfe, J. M. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.32 · Cited by 409 · cited 1×
“The present results suggesting undetectable Gd brain retention should also be validated in a more general population in individuals with neurological disorders and BBB disruption in different CNS regions, such as patients with PD [42,43], HD [20,44], human immunodeficiency virus–dementia [45– 47], and/or post-traumati…”
BackgroundDrouin‐Ouellet, J., Sawiak, S. J., Cisbani, G., Lagacé, M., Kuan, W., Saint‐Pierre, M., Dury, R. J., Alata, W., St‐Amour, I., Mason, S. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24406 · Cited by 288 · cited 2×
“The present results suggesting undetectable Gd brain retention should also be validated in a more general population in individuals with neurological disorders and BBB disruption in different CNS regions, such as patients with PD [42,43], HD [20,44], human immunodeficiency virus–dementia [45– 47], and/or post-traumati…”
BackgroundPhosphorylation of Claudin-5 and Occludin by Rho Kinase in Brain Endothelial Cells
Yamamoto, M., Ramirez, S. H., Sato, S., Kiyota, T., Cerny, R. L., Kaibuchi, K., Persidsky, Y., & Ikezu, T. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070076 · Cited by 241
Brain imaging of neurovascular dysfunction in Alzheimer’s disease
Montagne, A., Nation, D. A., Pa, J., Sweeney, M. D., Toga, A. W., & Zlokovic, B. V. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1570-0 · Cited by 239
Self-citationAlzheimer disease and aducanumab: adjusting our approach
Selkoe, D. J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0205-1 · Cited by 208 · cited 1×
“Aducanumab, a promising monoclonal antibody against Ab, was recently terminated in phase 3 clinical trials due to lack of efficacy despite its potent amyloid-clearing effect [50].”
BackgroundNeurovascular unit impairment in early Alzheimer's disease measured with magnetic resonance imaging
van de Haar, H. J., Jansen, J. F. A., van Osch, M. J. P., van Buchem, M. A., Muller, M., Wong, S. M., Hofman, P. A. M., Burgmans, S., Verhey, F. R. J., & Backes, W. H. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.006 · Cited by 207
Persidsky, Y., Heilman, D., Haorah, J., Zelivyanskaya, M., Persidsky, R., Weber, G. A., Shimokawa, H., Kaibuchi, K., & Ikezu, T. (2006) · Blood · doi:10.1182/blood-2005-11-4721 · Cited by 200
Hultman, K., Strickland, S., & Norris, E. H. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.76 · Cited by 183
Shedding of soluble platelet-derived growth factor receptor-β from human brain pericytes
Sagare, A. P., Sweeney, M. D., Makshanoff, J., & Zlokovic, B. V. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.09.025 · Cited by 142
Self-citationPienaar, I. S., Lee, C. H., Elson, J. L., McGuinness, L., Gentleman, S. M., Kalaria, R. N., & Dexter, D. T. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.12.006 · Cited by 125 · cited 1×
“The present results suggesting undetectable Gd brain retention should also be validated in a more general population in individuals with neurological disorders and BBB disruption in different CNS regions, such as patients with PD [42,43], HD [20,44], human immunodeficiency virus–dementia [45– 47], and/or post-traumati…”
BackgroundEffect of APOE genotype on microvascular basement membrane in Alzheimer's disease
Salloway, S., Gur, T., Berzin, T., Zipser, B., Correia, S., Hovanesian, V, Fallon, J., Kuo-Leblanc, V, Glass, D., Hulette, C., et al. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00288-5 · Cited by 113
Neurovascular abnormalities in humans and mice with Huntington's disease
Lin, C.-Y., Hsu, Y.-H., Lin, M.-H., Yang, T.-H., Chen, H.-M., Chen, Y.-C., Hsiao, H.-Y., Chen, C.-C., Chern, Y., & Chang, C. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.08.019 · Cited by 98
van de Haar, H. J., Jansen, J. F. A., Jeukens, C. R. L. P. N., Burgmans, S., van Buchem, M. A., Muller, M., Hofman, P. A. M., Verhey, F. R. J., van Osch, M. J. P., & Backes, W. H. (2017) · Medical Physics · doi:10.1002/mp.12328 · Cited by 85
Prevalence of cortical superficial siderosis in a memory clinic population
Zonneveld, H. I., Goos, J. D. C., Wattjes, M. P., Prins, N. D., Scheltens, P., van der Flier, W. M., Kuijer, J. P. A., Muller, M., & Barkhof, F. (2014) · Neurology · doi:10.1212/wnl.0000000000000150 · Cited by 78
Niu, F., Yao, H., Zhang, W., Sutliff, R. L., & Buch, S. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1139-14.2014 · Cited by 58
Cited by
APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281
Self-citationMou, Y., Du, Y., Zhou, L., Yue, J., Hu, X., Liu, Y., Chen, S., Lin, X., Zhang, G., Xiao, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.796288 · Cited by 432
Blood–brain barrier link to human cognitive impairment and Alzheimer’s disease
Barisano, G., Montagne, A., Kisler, K., Schneider, J. A., Wardlaw, J. M., & Zlokovic, B. V. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-021-00014-4 · Cited by 157
Self-citationYin, H., Lu, Z., Deng, Y., Tian, X., & Gong, Q. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102952 · Cited by 6
Metadata
- Authors
- Montagne, A., Huuskonen, M. T., Rajagopal, G., Sweeney, M. D., Nation, D. A., Sepehrband, F., D'Orazio, L. M., Harrington, M. G., Chui, H. C., Law, M., Toga, A. W., & Zlokovic, B. V.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2019-12
- Volume
- 15
- Issue
- 12
- Pages
- 1568-1575
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2995783541
- Cited by
- 32
- References
- 27
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.